Genmab AS - Company Profile
Powered by 
All the sales intelligence you need on Genmab AS in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Genmab AS fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Genmab AS.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Genmab AS (Genmab) is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The company's main activities include the discovery and development of next-generation therapeutic antibodies for treating cancer. Its major products include Tivdak, co-owned with Pfizer, and EPKINLY/TEPKINLY and others. The company's marketed antibodies include ofatumumab (Kesimpta) for the treatment of relapsing multiple sclerosis, daratumumab (Darzalex) for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan, and the US. Genmab is headquartered in Copenhagen, Denmark.
Headquarters
Denmark
Address
Carl Jacobsens Vej 30, Valby, 2500
Website
www.genmab.com
Telephone
45 70202728
No of Employees
2,682
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GMAB (CPH)
Revenue (2024)
$3.7B
19.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-15%
(2024 vs 2023)
Market Cap*
$18.2B
Net Profit Margin (2024)
XYZ
-28.7%
(2024 vs 2023)
* As of and is in US$
Genmab AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Kesimpta (Ofatumumab) – Relapsing Multiple Sclerosis | - |
| Darzalex (Daratumumab) – Multiple Myeloma | Darzalex |
| Tepezza (Teprotumumab) – Thyroid Eye Disease | Tepezza |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In November, the company announced that EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the US Food and Drug Administration for adult patients with relapsed or refractory follicular lymphoma. |
| 2025 | Contracts/Agreements | In September, the company entered into an agreement to acquire Merus, a clinical-stage biotechnology company. |
| 2025 | Regulatory Approval | In March, the company secured approval from Japan’s Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat patients with advanced or recurrent cervical cancer. |
Competitor Comparison
| Key Parameters | Genmab AS | Sanofi | Bayer AG | Takeda Pharmaceutical Co Ltd | Merck KGaA |
|---|---|---|---|---|---|
| Headquarters | Denmark | France | Germany | Japan | Germany |
| City | Valby | Paris | Leverkusen | Chuo-Ku | Darmstadt |
| State/Province | - | Ile-de-France | Nordrhein-Westfalen | Tokyo | Hessen |
| No. of Employees | 2,682 | 76,493 | 87,757 | 47,029 | 62,477 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Deirdre P. Connelly | Chairman | Executive Board | 2017 | 64 |
| Jan G. J. van de Winkel, Ph.D. | Chief Executive Officer; President | Senior Management | 2010 | 64 |
| Anthony Pagano | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 48 |
| Martine J. van Vugt | Executive Vice President; Chief Strategy Officer | Senior Management | 2023 | 55 |
| Birgitte Stephensen | Chief Legal Officer; Executive Vice President | Senior Management | 2022 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer